Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
31.44B
Market cap31.44B
Price-Earnings ratio
-99.99
Price-Earnings ratio-99.99
Dividend yield
Dividend yield
Average volume
1.27M
Average volume1.27M
High today
$229.22
High today$229.22
Low today
$225.80
Low today$225.80
Open price
$227.81
Open price$227.81
Volume
197.85K
Volume197.85K
52 Week high
$246.90
52 Week high$246.90
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

With a market cap of 31.44B, Natera(NTRA) trades at $227.29. The stock has a price-to-earnings ratio of -99.99.

During the trading session on 2025-12-16, Natera(NTRA) shares reached a daily high of $229.22 and a low of $225.80. At a current price of $227.29, the stock is +0.7% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 197.85K, compared to an average daily volume of 1.27M.

The stock's 52-week range extends from a low of $125.38 to a high of $246.90.

The stock's 52-week range extends from a low of $125.38 to a high of $246.90.

NTRA News

TipRanks 1d
NeoGenomics announce Natera withdrawal of appeal in patent litigation

NeoGenomics (NEO) announced that Natera (NTRA) voluntarily dismissed its appeal of the North Carolina District Court’s August 2025 ruling. The dismissal will le...

Simply Wall St 1d
Natera: Assessing Valuation After Strong Multi‑Year Share Price Rally

Natera (NTRA) shares have quietly outpaced much of the biotech space this year, climbing strongly on the back of double digit revenue growth and rapidly improvi...

Natera: Assessing Valuation After Strong Multi‑Year Share Price Rally
TipRanks 4d
Natera, Medica Scientia Innovation Research to collaborate on MiRaDoR study

Natera (NTRA) and Medica Scientia Innovation Research announced their collaboration on the MiRaDoR study, which is a multicenter, phase II clinical trial in hor...

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
9.1%
Sell
4.5%

More NTRA News

Benzinga 5d
Natera New Test Data Could Change How Doctors Manage Breast Cancer

Natera Inc. (NASDAQ:NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presen...

24/7 Wall St. 5d
Druckenmiller Invests $1.2 Billion in Natera, Insmed, and Teva Pharmaceuticals as Biotechs Rally

Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks Quick Read Natera (NTRA) grew revenue 34.66% year-over-year in Q3 2025 and has rall...

Druckenmiller Invests $1.2 Billion in Natera, Insmed, and Teva Pharmaceuticals as Biotechs Rally
TipRanks 6d
Natera announces initial translational research data from Phase 3 study

Natera (NTRA) “announced initial translational research results from the international randomized Phase III PALLAS study. Presented today at the San Antonio Bre...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.